Phase 4 N=31 Effect of Symbicort ® on GR in Sputum in COPD
Chronic Obstructive Lung Disease
Primary: GR-GRE Binding (Relative to Baseline) — 1.1; 1.8; 2.3; 2.1 Fold activation — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Parkinson Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 26.7; 100; 13.3 percentage of participants
Phase 2 N=37 A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
Multidrug Resistant Tuberculosis
Primary: Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE) — 7; 6; 12; 12 Participants
Phase 2 N=158 Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Investigator Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) 2-level Responders — 6; 131; 8; 125 Participants
Phase 3 N=426 Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Common Wart
Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants
N/A N=18 Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Phase 3 N=254 Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures
Progesterone Supplementation in Women Undergoing ART
Primary: Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval — 7.4 percentage of participants
Phase 4 N=11 Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
HIV Dementia
Primary: Change From Week 0 in Percentage of Blood Monocytes Expressing Surface Marker CD16 at 12 Weeks, as a Result of Treatment. — 1.14; 1.51 Fold change — p=0.39
Phase 2 N=112 Study of Efficacy of PEAR-004 in Schizophrenia
Schizophrenia
Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score — -1.6; -2.2; -2.5; -3.3 Score — p=0.0931
N/A N=21 Supporting Habit Formation to Attenuate Prefrailty in Elders: Pilot Study
Frailty
Primary: Number of Participants Completed the Study — 9; 11 Participants
Phase 2 N=225 Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Myelodysplastic Syndromes
Primary: Event-free Survival — 1440; 1091 days — p=0.015
Phase 2 N=39 An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Parkinson's Disease Psychosis
Primary: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 17 Participants
Phase 2 N=75 Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
B-cell Acute Lymphoblastic Leukemia · Relapsed B-cell Acute Lymphoblastic Leukemia · Refractory B-cell Acute Lymphoblastic Leukemia
Primary: Overall Remission Rate (ORR) Per Independent Review Committee (IRC) (for ALL Participants) — 70.3 Percentage of participants — p=<0.0001
Phase 3 N=1,538 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma (RCC) · Cancer
Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort